Analysts upgraded Taysha Gene Therapies' forecasts with increased revenue estimates, raising stock price targets.

Analysts have upgraded their forecasts for Taysha Gene Therapies, Inc. (NASDAQ:TSHA), with substantially increased revenue estimates and a 41% stock increase to $3.25. Needham & Company LLC raised their price target from $5.00 to $7.00, while Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 price target. The consensus rating for Taysha Gene Therapies is Buy, with a consensus price target of $6.57.